Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Apr 12;9(1):1420.
doi: 10.1038/s41467-018-03704-z.

Epigenetic control of IL-23 expression in keratinocytes is important for chronic skin inflammation

Affiliations

Epigenetic control of IL-23 expression in keratinocytes is important for chronic skin inflammation

Hui Li et al. Nat Commun. .

Abstract

The chronic skin inflammation psoriasis is crucially dependent on the IL-23/IL-17 cytokine axis. Although IL-23 is expressed by psoriatic keratinocytes and immune cells, only the immune cell-derived IL-23 is believed to be disease relevant. Here we use a genetic mouse model to show that keratinocyte-produced IL-23 is sufficient to cause a chronic skin inflammation with an IL-17 profile. Furthermore, we reveal a cell-autonomous nuclear function for the actin polymerizing molecule N-WASP, which controls IL-23 expression in keratinocytes by regulating the degradation of the histone methyltransferases G9a and GLP, and H3K9 dimethylation of the IL-23 promoter. This mechanism mediates the induction of IL-23 by TNF, a known inducer of IL-23 in psoriasis. Finally, in keratinocytes of psoriatic lesions a decrease in H3K9 dimethylation correlates with increased IL-23 expression, suggesting relevance for disease. Taken together, our data describe a molecular pathway where epigenetic regulation of keratinocytes can contribute to chronic skin inflammation.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Chronic skin inflammation in mice with a keratinocyte-restricted deletion of N-WASP. a H&E-stained back, tail, and perioral skin sections of 7-week-old mice (n: 6/6). Arrows indicate increased dermal cellularity. b Representative image of tails of 4-month (4m)-old control and ko mice. c K6 immunofluorescence of back skin section of at indicated ages (n: 4/4, mean ± SD, two-tailed unpaired t-test). d Quantification of Ki67+ cells in back skin epidermis sections (n: 4/4, mean ± SD, two-tailed unpaired t-test). e CD45 immunofluorescence of back skin at the indicated ages (n: 4/4). f FACS for CD45+ cells in back skin epidermis and quantification (n: 3/3, mean ± SD, two-tailed unpaired t-test). g Representative toluidine blue staining for mast cells and quantification of mast cell infiltration in numbers per field and ratio of dermal cells per field (n: 3/3, two-tailed unpaired t-test). Arrows indicate mast cells. Scale bars (a, c, e, g): 100 µm (*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001)
Fig. 2
Fig. 2
N-WASP knockout keratinocytes show multi-organ inflammation and autoimmunity. a Immunoblot analysis of IgG deposition in back skin at indicated ages. All normalized to GAPDH (n > = 3, mean ± SD, two-tailed unpaired t-test). b Representative immunofluorescence of IgG deposition of back skin and kidney at indicated ages (n: 3/3, mean ± SD, two-tailed unpaired t-test). Scale bar: 100 µm. c Representative image of inguinal lymph nodes (iLN) of con and ko mouse and quantification of cellularity of iLN at indicated ages (n: 3/3, mean ± SD, two-tailed unpaired t-test). d Representative image of kidneys of 4-month (4m)-old control and ko mice. e Representative of H&E staining of ureter. Scale bar: 50 µm. f Representative immunofluorescence staining of serum from con and ko (n: 8/8). g Detection of anti-dsDNA antibodies in serum (1:200) by ELISA (n: 4/4; mean ± SD, two-tailed unpaired t-test; *p ≤ 0.05)
Fig. 3
Fig. 3
Increased cytokine expression in N-WASP-null skin. a qRT-PCR analysis of indicated genes from back skin RNA of con and ko at indicated ages (n > = 3/3, two-tailed unpaired t-test). All normalized to GAPDH. b Representative toluidine blue staining for barrier defect in con and ko mice at indicated ages (P: E15.5 embryos used as positive controls; 2 days (2d) n: 6/5, 6 days(6d) n: 4/5, 3 independent experiments). c Representative immunofluorescence staining and quantification of IL-23p19 of con and ko back skin at indicated ages (n: 3/3, two-tailed paired t-test). Scale bar: 100 µm. d Representative sorting strategy of CD45+, α6H, and α6L cells from con and ko epidermal cells and qRT-PCR analysis of IL-23A and IL-17A expression in sorted cells (n: 3/3, mean ± SD, two-tailed unpaired t-test, 3 independent sortings). e Representative immunoblots and quantification of indicated proteins from epidermal lysates of 7–8-week old con and ko mice (n: 4/4, mean ± SD, two-tailed unpaired t-test). f Representative immunoblots and quantification of indicated proteins of co-precipitations of IL-23p19 with IL-12p40 from epidermal lysates of 7–8-week-old con and ko mice (n: 4/4, mean ± SD, two-tailed unpaired t-test; *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001)
Fig. 4
Fig. 4
Increased IL-17A-producing cells in N-WASP ko mice. a Representative and quantification of intracellular FACS analysis of IL-17A+ cells in epidermis (n: 3/3, mean ± SD, two-tailed unpaired t-test). b, c Representative and quantification of intracellular FACS analysis of IL-17A+ cells in iLN (n: 3/3, mean ± SD, two-tailed unpaired t-test). d, e Representative and quantification of CD4, CD8 distribution in thymus, spleen, and bone marrow from 9-day-old con and ko mice (n: 3/3, two-tailed unpaired t-test). f Representative H&E staining of thymus from 9-day-old con and ko mice (n: 3/3). Scale bar: 50 µm. g Representative and quantification of intracellular FACS analysis of IL-17A+ cells in mLN (n: 6/6, mean ± SD, two-tailed unpaired t-test; *p ≤ = 0.05; **p ≤ = 0.01; ****p ≤ = 0.0001)
Fig. 5
Fig. 5
Keratinocyte-derived IL-23p19 is important for skin inflammation in N-WASP knockout. a Strategy of loxP insertion in mouse IL-23A gene. b, c CD45, K6, Ki67 immunofluorescence of back skin section from 6-week-old con, ko, and dko (b), quantification of mean fluorescence intensity of CD45, and quantification of Ki67-positive cells in interfollicular epidermis (IFE) (n: 5/5/5, mean ± SD, one-way ANOVA, with Tukey’s multiple comparisons). Scale bar: 100 µm. d qRT-PCR analysis of indicated genes from back skin RNA 6–8-week-old of con, ko, and dko mice. All normalized to GAPDH (n > = 6/6/6, mean ± SD, one-way ANOVA, with Tukey’s multiple comparisons; *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001)
Fig. 6
Fig. 6
IL-23A expression is increased in N-WASP-null keratinocytes. a qRT-PCR analysis of indicated genes in FACS purified primary keratinocytes from 6-week-old mice (n: 4/4/4, mean ± SD, two-tailed unpaired t-test, 2 independent sorting). b qRT-PCR analysis of indicated cytokine mRNA expression in primary keratinocytes. All normalized to GAPDH (n: 3/3, mean ± SD, two-tailed unpaired t-test). c Primary keratinocytes were differentiated with 2 mM CaCl2 (High Ca2+) for 48 h and then analyzed by qRT-PCR for IL-23A expression, compared to untreated cells (Low Ca2+; n: 3/3, mean ± SD, two-tailed unpaired t-test). d qRT-PCR analysis of IL-23A mRNA expression in primary keratinocytes in response to 24 h treatment with indicated inhibitors. All normalized to GAPDH (n: 3/3, mean ± SD, two-tailed unpaired t-test). e Representative immunofluorescence of phalloidin in con and ko back skin. Scale bar: 100 µm. f Quantification of FACS mean fluorescence intensity of phalloidin in con and ko primary keratinocyte (n: 3/3, mean ± SD, two-tailed unpaired t-test). g qRT-PCR analysis of IL-23A mRNA expression in primary keratinocytes treated with indicated inhibitors for 24 h. All normalized to GAPDH. The right panel shows the same data, but normalized to the respective DMSO-treated samples, thus showing the relative effect of the treatment as fold change (n: 3/3, mean ± SD, two-tailed unpaired t-test; *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001)
Fig. 7
Fig. 7
N-WASP represses IL-23p19 expression in keratinocytes by regulating H3K9 dimethylation. a, b Immunoblot analysis of H3K9me2 level in con and ko primary keratinocytes treated with BIX01294 (a) or IOX-1 (b) for 24 h (n: 3/3, mean ± SD, one-way ANOVA, with Tukey’s multiple comparisons). c Immunoblot for H3K9me2 in epidermis of 6-day-old mice (n: 3/3, mean ± SD, two-tailed unpaired t-test). d H3K9me2 IF of back skin of 6-day-old mice (n: 3/3). Scale bar: 100 µm. e qRT-PCR analysis of IL-23A mRNA expression in sorted interfollicular epidermal keratinocytes from con and G9a knockout. All normalized to GAPDH (n: 4/4, mean ± SD, two-tailed unpaired t-test). f ChIP of primary keratinocytes for H3K9me2 with qPCR for indicated regions of IL-23 promoter (n: 7/7, mean ± SD, two-tailed unpaired t-test). g, h Primary N-WASP fl/fl cells lentivirally transduced with GFP or Cre-GFP were analyzed by western blot for indicated genes (g) and by qRT-PCR for IL-23A expression (h; n: 4/4, mean ± SD, two-tailed unpaired t-test; *p ≤0.05; **p ≤ 0.01; ***p ≤ 0.001)
Fig. 8
Fig. 8
N-WASP co-precipitates with and regulates the stability of the H3K9 methyltransferases G9a and GLP. Expression of G9a and GLP mRNA (a, b) and protein (c, d) in epidermis of 6-day-old mice (a, c) and in primary keratinocytes (b, d). (n (a, b, c): 3/3; n (d): 5/5). e immunoblot analysis of protein stability of G9a and GLP in primary keratinocytes in the presence of cycloheximide (G9a n: 4/4, GLP n: 6/6, mean ± SD, two-tailed unpaired t-test). f Cell fractionation of keratinocytes after 90 min of treatment with the proteasome inhibitor MG-132 followed by immunoblot for indicated proteins, the indicated protein levels were quantified on the right (n: 3/3, mean ± SD, two-tailed unpaired t-test). g Cell fractionation of primary keratinocytes with treatment of the pellet fraction with micrococcal nuclease followed by immunoblot for indicated proteins (MNase) (n: 3). h Co-precipitation of N-WASP with G9a and GLP in primary keratinocyte nuclear lysates (n: 3). C: cytosolic fraction, SN: soluble nuclear fraction, P: pallet (*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001)
Fig. 9
Fig. 9
TNF regulates IL-23A expression by phosphorylating N-WASP and degradation of G9a/GLP complex. a qRT-PCR analysis of IL-23A mRNA expression in con and ko primary keratinocytes treated for 4 h with TNFα (n: 3/3, mean ± SD, two-tailed unpaired t-test). b FACS analysis of surface TNF-RI in primary keratinocytes (n: 3/3, two-tailed unpaired t-test). c Primary keratinocytes were treated for indicated times with TNFα and then tested by immunoblot for expression of indicated proteins (n: 4/4). d Primary keratinocytes were treated for indicated time with TNF, fractionated, and analyzed by immunoblot for indicated proteins (C: cytosolic fraction, S300: soluble nuclear fraction extracted by 300 mM NaCl, P300: pellet after 300 mM NaCl extraction, SE: short exposure, LE: long exposure; n: 3). e ChIP of primary keratinocytes for H3K9me2 with qRT-PCR for indicated regions of IL-23A promoter after treatment with TNFα for indicated times (n: 5/5, mean ± SD, two-tailed unpaired t-test). f qRT-PCR analysis of IL-23A mRNA expression in con and ko primary keratinocytes pretreated with or without IOX-1 for 24 h and then stimulated with or without TNFα for 4 h as indicated. All normalized to GAPDH (n: 4/4, mean ± SD, two-tailed unpaired t-test; *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001)
Fig. 10
Fig. 10
Decreased H3K9me2 in psoriatic lesions correlating with increased IL-23p19 expression. a, b H3K9me2 staining (a) and quantification (b) in healthy skin, non-lesioned and lesioned psoriatic skin (n: 3/3, mean ± SD, one-way ANOVA, with Tukey’s multiple comparisons). c H3K9me2 and IL-23p19 staining in non-lesioned and lesioned psoriatic skin (n: 3/3). Scale bars: 100 µm (a, c). (*p ≤ = 0.05; **p ≤ = 0.01)

Similar articles

Cited by

References

    1. Nestle FO, Kaplan DH, Barker J. Psoriasis. N. Engl. J. Med. 2009;361:496–509. doi: 10.1056/NEJMra0804595. - DOI - PubMed
    1. Kim J, Krueger JG. The immunopathogenesis of psoriasis. Dermatol. Clin. 2015;33:13–23. doi: 10.1016/j.det.2014.09.002. - DOI - PubMed
    1. Campa M, Menter A. A review of emerging IL-17 inhibitors in the treatment of psoriasis focusing on preclinical through phase II studies. Expert Opin. Investig. Drugs. 2016;25:1337–1344. doi: 10.1080/13543784.2016.1237502. - DOI - PubMed
    1. Suarez-Farinas M, et al. Alopecia areata profiling shows TH1, TH2, and IL-23 cytokine activation without parallel TH17/TH22 skewing. J. Allergy Clin. Immunol. 2015;136:1277–1287. doi: 10.1016/j.jaci.2015.06.032. - DOI - PubMed
    1. Wong CK, et al. Hyperproduction of IL-23 and IL-17 in patients with systemic lupus erythematosus: implications for Th17-mediated inflammation in auto-immunity. Clin. Immunol. 2008;127:385–393. doi: 10.1016/j.clim.2008.01.019. - DOI - PubMed

Publication types

MeSH terms